Archive for the ‘Bone Marrow Stem Cells’ Category

When Dr Yendry Ventura began work to set up the Abu Dhabi Stem Cell Centre in late 2018, there was, he says, nothing else "related to stem cell therapy in the emirate.

Fast forward to today and the situation has changed dramatically. After opening in December last year, the centre has already received international press coverage over to its research into a treatment for Covid-19.

Their groundbreaking work has involved taking stem cells from a patients blood and returning them, via a nebuliser, as a fine mist to the lungs.

There they help regenerate lung cells and improve the body's immune response by preventing an overreaction to the infection that can damage healthy cells.

What characterises the method, says Dr Ventura, is that very little manipulation of the cells is needed for the treatment to be effective.

The future for the stem cells lies in regenerative medicine, in which you can treat almost all the degenerative conditions.

Dr Yendry Ventura

We separate a specific layer of cells from the blood, Dr Ventura told The National. Were the first one to use these cells with this route with this method.

We believe this way the cells can be aimed much better to the affected organs - the upper and lower respiratory tract.

In April, the centres efforts to develop a Covid-19 treatment led to the recovery of all 73 patients the treatment was initially trialled on. A quarter had been in intensive care.

The results appeared so promising that this month the centre secured intellectual property rights to the technique, allowing the treatment to be widely licensed, including to facilities abroad.

The ongoing work exemplifies how the centres specialists have been able to apply their expertise to help in a time of crisis, Dr Ventura said.

But the new research is a departure from the facilitys usual purpose, which involves developing cutting-edge stem cell treatments for conditions such as cancer and heart disease.

Stem cells were first extracted from humans and grown in laboratories less than a quarter of a century ago.

The human body is mostly made of specialised cell types, such as heart muscle cells, kidney cells or nerve cells, all of which have a particular form related to their function.

Stem cells, however, have not yet undergone the process of developing into a specialised cell type, and are able to be manipulated to perform a specific function.

In adults, stem cells are found in tissues including fat and bone marrow, and these can be turned into cell types.

One technique that the Abu Dhabi Stem Cell Centre plans to implement is haematopoietic stem cell transplantation, which involves stem cells being removed from an individual who is due to have cancer treatment.

The cells are then processed in a laboratory and injected into the patient after they have undergone chemotherapy or radiotherapy.

In this way, they can replace stem cells destroyed by the treatment, allowing a patient to tolerate a higher dose of therapy.

Dr Ventura says that similar treatments were applicable to most cancers of the blood as well as cancers that produce solid tumours.

There are many of these therapies still in research stage, but if you conquer this research, you can have a programme in which you can ... treat many kinds of cancers at the same time in one centre, he said.

The reality is that cell therapy is curing cancer We need to improve this therapy and make it available for many other people.

The future for the stem cells lies in regenerative medicine, in which you can treat almost all the degenerative conditions.

You can create in the future, if you have the right technologies, even artificial organs.

Set up with private sector funding in collaboration with the UAE authorities, the Abu Dhabi Stem Cell Centre works closely with experts at Sheikh Khalifa Medical City.

But the institution is keen to forge further partnerships with both public and private sector medical institutions.

Currently, it operates seven days a week and has more than 100 staff, including nurses, technicians and doctors who specialise in immunology, haematology, pathology, orthopaedics, urology and radiology.

In another initiative, the facility has recently begun running Minimal Residual Disease tests, which look at how many malignant cells remain in a patients blood or bone marrow.

These tests are useful for people with a variety of blood cancers, including lymphoma, leukaemia and myeloma. But they require fresh samples from the patient, so the lack of UAE testing facilities has, until now, required patients to travel abroad.

We try to implement the tests here in the Abu Dhabi Stem Cell Centre so that the patient does not need to travel anymore, said Dr Ventura.

Updated: June 16, 2020 02:01 PM

The rest is here:
Coronavirus: inside the UAE stem cell centre working to treat Covid-19 - The National

Hematopoietic Stem Cell Transplantation (HSCT) Market report provide the COVID19 Outbreak Impact analysis of key factors influencing the growth of the market Size (Production, Value and Consumption). This Hematopoietic Stem Cell Transplantation (HSCT) industry splits the breakdown (data status 2014-2020 and Six years forecast 2020-2026), by manufacturers, region, type and application. This study also analyses the Hematopoietic Stem Cell Transplantation (HSCT) market Status, Market Share, Growth Rate, Future Trends, Market Drivers, Opportunities and Challenges, Risks and Entry Barriers, Sales Channels, Distributors and Porters Five Forces Analysis.

Hematopoietic Stem Cell Transplantation (HSCT) Market competitive landscapes provides details by topmost manufactures like (Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc), including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Hematopoietic Stem Cell Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2276986

Hematopoietic Stem Cell Transplantation (HSCT) Market Competition by Manufacturers (2020 2026): Hematopoietic Stem Cell Transplantation (HSCT) Market Share of Top 3 and Top 5 Manufacturers, Hematopoietic Stem Cell Transplantation (HSCT) Market by Capacity, Production and Share by Manufacturers, Revenue and Share by Manufacturers, Average Price by Manufacturers By Market, Manufacturers Manufacturing Base Distribution, Sales Area, Product Type, Market Competitive Situation and Trends, Market Concentration Rate.

Scope of Hematopoietic Stem Cell Transplantation (HSCT) Market:In 2019, the market size of Hematopoietic Stem Cell Transplantation (HSCT) is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hematopoietic Stem Cell Transplantation (HSCT).

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Allogeneic Autologous

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Peripheral Blood Stem Cells Transplant (PBSCT) Bone Marrow Transplant (BMT) Cord Blood Transplant (CBT)

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2276986

Hematopoietic Stem Cell Transplantation (HSCT) Market: Regional analysis includes:

The Study Objectives Of This Hematopoietic Stem Cell Transplantation (HSCT) Market Report Are:

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

See the original post here:
Hematopoietic Stem Cell Transplantation (HSCT) Market Segments, Opportunity, Growth and Forecast by End-use Idustry 2020-2026 - Cole of Duty

The speed of change is fascinating

As we head into the 2020s, tech developers and medical scientists are working hard to ensure that we stay healthy and well-cared for, for as long as possible. Here are some of the big healthcare innovations making waves at the moment.

Artificial blood has been proposed for a number of years, but it is only recently that it has gained any sort of traction in medical circles. The science behind it is simple to understand while no doubt actually being incredibly complex. Artificial blood does not seek to replace blood entirely but instead to supplement red blood cells in the body, to carry oxygen where it needs to be delivered.

These blood cells are called artificial as they are generated in a lab environment instead of a human body and are grown from stem cells. Researchers typically use hematopoietic stem cells taken from bone marrow for growing such cells. With blood donation dropping, this could be a timely solution to support healthcare professionals alongside blood donation drives.

Blindness is a massive issue no matter where you live on the planet. In particular, corneal blindness is the fourth most common blindness in the world. However, there is now a solution that is cheap and easy to deliver, and that could make a massive difference to many people.

Many are now coming forward to support medical staff in their endeavours in this sector. Tej and Wendy Kohli are key voices in creating help here. Following other charitable givers like Bill and Melissa Gates and Warren Buffett, it is clear that input from top figures like this is crucial in supporting a cause and seeing it develop into a system that could genuinely make a difference.

The ability to use genetic information to come up with a treatment plan for a patient is a precise art. However, research into the world of genomics is making this a much more viable method of treatment than it has previously.

The scope for this is massive. So much of our response to certain treatments can be bound up in our genetics and research here could change medicine forever. With setbacks like organ transplant rejection and gene mutation still having a major impact on medicine as a whole, it is incredibly important that researchers work to find a solution that works around these issues. Comprehensive and detailed genomics might be it.

All three of these areas have seen some massive leaps forward in the past month. No matter what, focus needs to be kept on these key areas in the future. Only then will we see some massive improvements that could shape our healthcare for the better. These developments could lead to the complex becoming the norm in worldwide healthcare.

Developments made today might one day be celebrated as pioneering breakthroughs that helped to transform healthcare and the lives of humanity.

Here is the original post:
Healthcare innovations making waves in 2020 - Crawley Observer

People with cancer may have compromised immunity due to their disease or its treatment. Early reports suggest cancer is a risk factor for severe COVID-19 disease as a result, many patients with cancer, and their families, are concerned about the risks and impacts of COVID-19.

Their concerns and distress are likely to be compounded by extensive media coverage of the pandemic, rapid changes in information about COVID-19 and continuing uncertainty about how to contain the disease.

On top of this, community transmission of COVID-19 has threatened the capacity of cancer services to provide routine investigations and care. In some cases, this has seen a prioritisation or modification of patients cancer therapies.

For example, chemotherapy may be postponed as this can compromise the immune system and make patients more vulnerable to developing COVID-19 disease.

Patients and families may, in turn, be frightened about not receiving proper treatment.

Read more

Another cause for concern is the change in the routine clinical management of cancer patients, partly because patients fear being infected. In Victoria, cancer hospitals have reported a 40 per cent decline in patient presentations for cancer management appointments since the stay-at-home guidelines in late March 2020.

This has raised concern among oncology health professionals about the health and wellbeing of vulnerable cancer patients whose health outcomes are likely to be negatively affected.

As patients are presenting less to hospital, it becomes crucial to develop new ways of identifying any distress in order to provide high-quality cancer management and supportive care.

The restrictions imposed by governments have been effective in limiting the spread of COVID-19, but social distancing, quarantine and visitor limitations have also reduced the opportunity for family support and connection important sources of strength and wellbeing.

These same government restrictions have also increased the use of telehealth to deliver care to cancer patients during COVID-19. Telehealth tools include simple patient health portal messages to relieve triage phone lines, e-consultation and telephone or video-based virtual visits.

Read more

The latest data from the Victorian COVID-19 Cancer Networks Telehealth Expert Group found that all of Victorias health services were now using telehealth for cancer care. And these tools may continue to expand, allowing greater access to supportive care beyond this crisis.

However, as useful as it is, this technology may pose issues of trust, isolation, disconnectedness and worries about abandonment as patients no longer benefit from the reassuring structure of the hospital oncology setting.

Telehealth may also not be possible for patients without a computer or internet access, which may create inequities in psychosocial care.

These issues should be considered if we upscale telehealth procedures for cancer patients and want to keep the best changes after the pandemic.

With respect to COVID-19, people with blood cancer are a particularly vulnerable group and require specialised attention and care. This is because blood cancers affect the production and functions of cells created in the bone marrow, which produces all the cells of our immune system.

Additionally, treatment for blood cancers compromise the immune system further, placing patients at very high risk of opportunistic infections, often for an extended period.

Read more

Even common respiratory viruses, like colds, can threaten survival. As a result, blood cancer specialists have recommended heightened surveillance and protective isolation for people with blood cancers.

A second major issue for blood cancer patients during the COVID-19 pandemic is the availability of donor stem cell products for patients undergoing haematopoietic stem cell transplantation.

Approximately 350 stem cell transplants are performed in Australia every year to treat blood cancers like leukaemia and multiple myeloma.

But finding a suitable stem cell donor is incredibly challenging, and about 80 per cent of donated stem cells come from overseas donors.

Unfortunately, COVID-19 has impacted donor availability due to border restrictions, flight changes and fear of becoming infected, creating very fearful scenarios for those waiting for potentially life-saving stem cell transplantation.

Victoria has already reported a case of a donor cancellation at short notice because the donor was worried about having been in contact with somebody with COVID-19.

The emotional consequences of the COVID-19 pandemic for people with blood cancers cannot be underestimated, nor can the consequences for the healthcare providers who care for them.

Read more

The COVID-19 pandemic has had a serious and disruptive effect.

In the short term, staff and resources at many hospitals have been reassigned to manage the rush of patients with COVID-19. Healthcare providers are faced with ethical dilemmas and required to make difficult treatment decisions without evidence-based guidelines.

Estimating the risk versus the benefit of administering potentially immunosuppressive treatment to patients with haematological cancers with a scarcity of knowledge about this novel disease, and balancing the individual and societal benefits with stretched resources, poses acute ethical dilemmas.

Making these challenging decisions can create fertile grounds for burnout and trauma.

More than ever, we need to develop ways to nurture healthcare providers.

Consideration of their unique experiences and needs during these exceptionally difficult times is important and we need to flexibly develop services to respond to those needs now and beyond this crisis.

But in developing such services, as well as recognising unmet needs, we have to acknowledge the problem-solving skills, resourcefulness and innovation that patients and healthcare providers have already undertaken as they have strived to adapt to managing cancer during COVID-19.

Banner: Getty Images

Read this article:
COVID-19 and cancer care - Pursuit

COVID-19 impact will also be included and considered for forecast.

Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Thalassemia Treatment Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=57&RequestType=Sample

Global Thalassemia Treatment Market 2018-2024Brandessence Market Research is working on a new report titleGlobal Thalassemia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?. Rise in number of altered Thalassemia genes, increase in awareness about the disease and high adoption of chelation therapy & blood transfusion for treatment by doctors as well as patients arelikely to enhance the growth of Global Thalassemia Treatment Market.

Scope of Global Thalassemia Treatment Market Reports

Thalassemia is aninherited blood disorder in which the body makes an abnormal form of hemoglobin.People having Thalassemia disease are unable to make sufficient hemoglobin which causes severe anemic conditions.Hemoglobin is found in red blood cells and transports oxygen to all parts of the body. When there is insufficient hemoglobin in the red blood cells, oxygen cannot get to all parts of the body. Organs demand oxygen and are unable to function properly.There are two primary types of Thalassemia disease such as Alpha Thalassemia disease and Beta Thalassemia disease.Alpha Thalassemia results in a formation of additional beta globins, which leads to the formation of beta-globin tetramers (4) called Hemoglobin H.

Beta Thalassemia causesadditionalformation of alpha globins, which develops alpha globin tetramers (a4) that store in the erythroblast (immature red blood cell).Thalassemia is caused by mutations in the DNA of cells that make hemoglobin.

Factors that increase risk of Thalassemia include Family history of thalassemia and certain ancestry.Possible complications of Thalassemia includeIron overload, Infections, Bone deformities, splenomegaly, slowed growth rate of child and Heart problems.

Thalassemia signs and symptoms include Fatigue, Weakness, Pale or yellowish skin, Facial bone deformities, slow growth, abdominal swelling, Dark urine, chest pain,cold hands and feet, poor feeding, greater susceptibility to infections. Diagnosis of Thalassemia includesa complete blood count (CBC), a reticulocyte count,Iron count, Genetic testing and prenatal testing. Treatment of Thalassemia depends on the type and severity of Thalassemia such as Blood transfusions, Bone marrow or stem cell transplant, Surgery and Gene therapy.

Global Thalassemia Treatment Market has been segmented on the basis ofType of Treatment, Diagnosis, End usersand Geography. On the basis of Type of TreatmentGlobal Thalassemia Treatment Market is classified into Blood Transfusion, Chelating Therapy, Bone Marrow Transplant, Stem Cell Transplant, Surgery, Gene Therapy and Others.On the basis of DiagnosisGlobal Thalassemia Treatment Market is classified into Perinatal Testing, Prenatal Testing, Pre-Implantation and Other.On the basis of the End user the Global Thalassemia Treatment Market is classified into Hospitals, Biotechnological Laboratories, Diagnostic Laboratories, Educational Research Institutes, Pharmaceutical Industries and others.

The regions covered in Global Thalassemia Treatment Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Thalassemia Treatment Market Reports

Global Thalassemia Treatment Market reports cover prominent players like Bluebird bio Inc., Acceleron Pharma Inc., Novartis AG, Celgene Corporation, Shire plc, Bellicum Pharmaceuticals, GlaxoSmithKline Plc, Celgene,Lonza group, Alnylam Pharmaceuticals Inc., Calimmune Inc., CRISPR Therapeutics, Editas Medicine Inc., Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc., Incyte Corp, Ionis Pharmaceuticals Inc., IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc., PharmaEssentia Corp, Protagonist Therapeutics Inc., Sangamo Therapeutics Inc., Zydus Cadila Healthcare Ltd, Genorama Ltd, HiMedia Laboratories, DiagCor Bioscience Inc. Ltd and Tosoh Bioscience Inc.

Global Thalassemia Treatment Market Dynamics

Increase in awareness about the disease and technological expansions are likely to raise the adoption of gene therapies. Also Rising Prevalence of Thalassemia, Increase in Pharmaceutical R&D Spending, Increasing Spending on Stem Cell Research, Rising Healthcare Expenditure and Rising Asian Population will boost theGlobal Thalassemia Treatment Market. Treatment of Thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy.Moreover, High operation cost of sophisticated clinical and preclinical imaging systems, High cost of maintenance andless life span of accessoriesalso restraining theGlobal Thalassemia Treatment Market.Yearlyspending for treatment of Thalassemia ranged from $ 108 to 432, depending on type of treatment with average cost per blood transfusion was $ 5.22.2. Average 18.5%14.3 of the total annual income was spent on the treatment for Thalassemia. Drugs prescribed for Thalassemia mostly cures symptoms and side effects such as anemia, iron overload, slow growth of children and vitamin deficiency.Occurrence of Thalassemia is reported to increase steadily over the years across different regions. This can be due to population migration, intermarriages, genetic as well as environmental factors prompting the condition and its implications.Systematic Drugs under Pipeline, Rising Scope for Gene Therapy and increasing awareness towards Thalassemia are some opportunities in the forecast period for theGlobal Thalassemia Treatment Market.

Global Thalassemia Treatment MarketRegional Analysis

North America have largest share ofGlobal Thalassemia Treatment Market. It is mainly driven by quickly increasing immigrant population from tropical regions, rising number of population with Thalassemia carrier gene and rise in birth rates due to variation of genes among the population in the U.S.There are some prenatal tests available on the market to determine the possibility of alpha thalassemia including both invasive and non-invasive technique.

The alpha thalassemia testing market has aemergent trend in the countries with traditional groups like Mediterranean countries, African countries and few countries in Asia Pacific. Furthermore, in Asia Pacific region the growth in similar community marriage practices and high fertility ratewith alpha thalassemia patients have been detected. This is expected to raiseacceptance of blood transfusion and chelation therapy treatments during the forecast period.A latestimprovement in the testing of alpha Thalassemia may determine the risk of the disease by in vitro examination of the embryo. While there are various such tests available in theGlobal Thalassemia Treatment Market but lack of awareness leads to the neglect and delayed diagnosis of the diseased state.

Most frequently prone area for alpha thalassemia is Mediterranean countries, African countries, and Southeast Asian countries. Thalassemia trait practically affects 6% to 35% of the population in these ethnic groups. Middle East & Africa is likely to be the fastest risingGlobal Thalassemia Treatment Market during the forecast period.

Key Benefits for Global Thalassemia Treatment Market Reports

Global Thalassemia Treatment Market report covers in depth historical and forecast analysis.Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Global Thalassemia Treatment Market report helps to identify opportunities in market place.Global Thalassemia Treatment Market report covers extensive analysis of emerging trends and competitive landscape.Global Thalassemia Treatment Market Segmentation

Global Thalassemia Treatment Market: By Type of Treatment Analysis

Blood TransfusionChelating TherapyBone Marrow TransplantStem Cell TransplantSurgeryGene TherapyOtherGlobal Thalassemia Treatment Market: By Diagnosis Analysis

Perinatal TestingPrenatal TestingPre-ImplantationOtherGlobal Thalassemia Treatment Market: By End user Analysis

HospitalsBiotechnological LaboratoriesDiagnostic LaboratoriesEducational Research InstitutesPharmaceutical IndustriesOtherGlobal Thalassemia Treatment Market: By Regional & Country Analysis

North AmericaU.S.MexicoCanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilThe Middle East and AfricaGCCAfricaRest of Middle East and AfricaNeed a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=57&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Thalassemia Treatment Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Thalassemia Treatment Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Thalassemia Treatment Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Thalassemia Treatment Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Thalassemia Treatment Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Thalassemia Treatment Market.

Market Forecast: Here, the report offers a complete forecast of the Global Thalassemia Treatment Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Read more here:
2025 Projection: Thalassemia Treatment Market Analysis by SWOT, Investment, Future Growth and Major Key Players 2020 to 2026 - Cole of Duty

Management to Host One-on-One Investment Meetings

NEW YORK, June 11, 2020 /PRNewswire/ --BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits, CEO and Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview on Thursday, June 18 at 9:00 am EST, during theRaymond James Human Health Innovations Conference, a virtual event connecting institutional investors with company management teams that will be held June 15-18, 2020.

Mr. Lebovits and Dr. Kern will update conference participants on the Company's investigational therapeutic, NurOwn, that is currently in a fully enrolled phase 3 study for the treatment of ALS and a phase 2 study for the treatment of progressive multiple sclerosis. Additionally, they will present an overview of the Company's financial position and pipeline. After the presentation, the management team will participate in a question and answer session with institutional investors.

Mr. Lebovits and Dr. Kern will be joined by David Setboun, PhD, MBA, Chief Operating Officer, Stacy Lindborg, PhD, Head of Global Clinical Research, and Preetam Shah, PhD, MBA, Chief Financial Officer, for a series of one-on-one meetings, with select institutional investors arranged by Raymond James.

Participants can view the presentation via the event link and those unable to join will have access to an archived link on the Company's Events and Presentation webpage after the conclusion of the conference.

EVENT: Raymond James Human Health Innovations Conference

PRESENTATION: Thursday, June 18th at 9:00 am EST

LINK: https://bit.ly/2YmZf8u

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently receivedU.S.FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began inMarch 2019.

AboutBrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment inMarch 2019.

Story continues

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: +1-862-397-1860pshah@brainstorm-cell.com

Media:

Sean LeousWestwicke/ICR PRPhone: +1-646-677-1839sean.leous@icrinc.com

View original content:http://www.prnewswire.com/news-releases/brainstorm-to-present-at-the-raymond-james-human-health-innovations-conference-301074370.html

SOURCE Brainstorm Cell Therapeutics Inc

Visit link:
BrainStorm to Present at the Raymond James Human Health Innovations Conference - Yahoo Finance

On Friday, June 5, a few days after World MS Day on May 30, there was a day of online conferences and workshops to learn more about multiple sclerosis. It was an opportunity to shed light on autologous bone marrow transplantation, a little known treatment that could cure multiple sclerosis.

Neuron

Multiple sclerosis (MS) is a neurodegenerative autoimmune disease that causes stiffness, pain, and fatigue. It is the main cause of disability, exclusion from the labor market, and social exclusion among young people, as it occurs mainly among people between 25 and 35 years old. According to the National MS Society, approximately 1 million people in the United States suffer from MS.

Currently, there is no treatment to cure MS, but there is hope: Autologous bone marrow transplantation or autologous hematopoietic stem cell transplantation. This treatment allows patients to go from the more common forms of multiple sclerosis into remission. If carried out early enough, it enables at least partial recovery from the disability.

Read Also: Combo of Diabetes and Hypertension Drugs Causes Cancer Cell Death, Researchers Find

The aim of this treatment is to rebuild a new immune system in patients. This includes intensive chemotherapy followed by reinjection of the patients hematopoietic stem cells. Several studies conducted between 2015 and 2019 on this technique have shown that 83.3 of patients with the relapsing-remitting form had no attack in the four years following auto-transplantation and three years after transplantation 78% of patients with secondary progressive multiple sclerosis and 66% of patients with primary progressive multiple sclerosis experienced no worsening of their disability, Mediapart continues.

One of the main obstacles to this treatment remains the difficulty of access. Many patients testify that their neurologist often finds this method too experimental and too risky. Another factor that discourages the use of autologous bone marrow transplantation is the risk-benefit ratio, which is considered unbalanced. Transplant-related mortality is between 5 and 10%, which justifies doctors preference for a treatment that is considered safer.

Read Also: Diabetes: Metformin Transfers Blood Sugar From the Blood to the Intestines

Another treatment has shown encouraging results in multiple sclerosis. This is a drug for diabetes, metformin, which rejuvenates stem cells to convert them into myelin-producing cells and thus help combat multiple sclerosis. These results have been published in the journal Cell Stem Cell, and it is expected that the tests, which are currently only carried out on mice, will also be carried out on humans within a year. I am very optimistic, study author Professor Robin Franklin told The Guardian newspaper.

References

Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells

https://blogs.mediapart.fr/noelle-tassy/blog/300520/journee-mondiale-de-la-sep-et-si-parlait-du-traitement-dont-ne-parle-pas

Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents

Read the original:
Autologous Bone Marrow Transplantation and Metformin, a Hope for the Cure of Multiple Sclerosis - Gilmore Health News

The company said the move was aimed at the development of next generation cellular immunotherapy FLASH-CAR technology

(), a clinical-stage developer of cell-based technologies and therapeutics, announced Thursday that it has struck a three-way material transfer agreement (MTA) with Weill Cornell Medicine in New York City and the companys strategic partner, Arbele Limited.

With this agreement, Avalon GloboCare and Arbele Limited intend to collaborate with Weill Cornell Medicine and co-develop the standardized laboratory steps necessary to generate clinical-grade CAR-T and CAR-natural killer (NK) cells for use in future human clinical trials with Avalons first FLASH-CAR platform candidate, AVA-011.Similar to T-cells, NK cells are a type of white blood cell, also able to attack cancer cells, but utilize different mechanisms.

The company said this process development step will provide the bridge between Avalons benchtop research and the bio-manufacturing processes to potentially deliver the clinical-grade cellular immunotherapy product to patients.

READ:Avalon GloboCare advancing immune cell therapy to treat blood cancers using FLASH-CAR technology

We are excited about this agreement to translate our cellular therapy candidates into standardized, clinical-grade cell products that could be used in future clinical trials, Avalon GloboCare CEO David Jin said in a statement.

This step reflects our dedication to establishing an infrastructure to develop our cellular immunotherapy candidates and to maintain the highest possible standards for generating clinical-grade cells for human cancer trials, he added.

AVA-011 is a next generation cellular immunotherapy candidate using Avalons FLASH-CAR technology that targets both CD19 and CD22 tumor antigens on cancer cells. Avalon has already successfully completed pre-clinical research on AVA-011, including tumor cytotoxicity studies.

Avalon expects to begin a first-in-human clinical trial with AVA-011 for the treatment of relapsed or refractory B-cell lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma in the first quarter of 2021. The goal is to use AVA-011 as a bridge to bone marrow stem cell transplant therapy, currently the only curative approach for patients with these blood cancers.

Avalons next generation immune cell therapy using FLASH-CAR technology is being co-developed with the companys strategic partner Arbele Limited. The adaptable FLASH-CAR platform can be used to create personalized cell therapy from a patients own cells, as well as off-the-shelf cell therapy from a universal donor, expanding the reach of cancer patients that can be treated.

Avalon, based in Freehold, New Jersey, specializes in developing cell-based technologies and is involved in the management of stem-cell banks and clinical laboratories.

Contact the author Uttara Choudhury at [emailprotected]

Follow her on Twitter: @UttaraProactive

See the original post here:
Avalon GloboCare strikes three-way material transfer agreement with Weill Cornell Medicine and Arbele Limited - Proactive Investors USA & Canada

The Hematopoietic Stem Cell Transplantation (HSCT) Market research report enhanced worldwide Coronavirus COVID19 impact analysis on the market size (Value, Production and Consumption), splits the breakdown (Data Status 2014-2020 and 6 Year Forecast From 2020 to 2026), by region, manufacturers, type and End User/application. This Hematopoietic Stem Cell Transplantation (HSCT) market report covers the worldwide top manufacturers like (Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc) which including information such as: Capacity, Production, Price, Sales, Revenue, Shipment, Gross, Gross Profit, Import, Export, Interview Record, Business Distribution etc., these data help the consumer know about the Hematopoietic Stem Cell Transplantation (HSCT) market competitors better. It covers Regional Segment Analysis, Type, Application, Major Manufactures, Hematopoietic Stem Cell Transplantation (HSCT) Industry Chain Analysis, Competitive Insights and Macroeconomic Analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Hematopoietic Stem Cell Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2276986

Hematopoietic Stem Cell Transplantation (HSCT) Market report offers comprehensive assessment of 1) Executive Summary, 2) Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Hematopoietic Stem Cell Transplantation (HSCT) Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Hematopoietic Stem Cell Transplantation (HSCT) Market Background, 7) Hematopoietic Stem Cell Transplantation (HSCT) industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Hematopoietic Stem Cell Transplantation (HSCT) Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles, 11) Assumptions and Acronyms and, 12) Research Methodology etc.

Scope of Hematopoietic Stem Cell Transplantation (HSCT) Market:In 2019, the market size of Hematopoietic Stem Cell Transplantation (HSCT) is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hematopoietic Stem Cell Transplantation (HSCT).

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Peripheral Blood Stem Cells Transplant (PBSCT) Bone Marrow Transplant (BMT) Cord Blood Transplant (CBT)

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Allogeneic Autologous

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2276986

Geographically, the report includes the research on production, consumption, revenue, Hematopoietic Stem Cell Transplantation (HSCT) market share and growth rate, and forecast (2020-2026) of the following regions:

Important Hematopoietic Stem Cell Transplantation (HSCT) Market Data Available In This Report:

Strategic Recommendations, Forecast Growth Areasof the Hematopoietic Stem Cell Transplantation (HSCT) Market.

Challengesfor the New Entrants,TrendsMarketDrivers.

Emerging Opportunities,Competitive Landscape,Revenue Shareof Main Manufacturers.

This Report Discusses the Hematopoietic Stem Cell Transplantation (HSCT) MarketSummary; MarketScopeGives A BriefOutlineof theHematopoietic Stem Cell Transplantation (HSCT) Market.

Key Performing Regions (APAC, EMEA, Americas) Along With Their Major Countries Are Detailed In This Report.

Company Profiles, Product Analysis,Marketing Strategies, Emerging Market Segments and Comprehensive Analysis of Hematopoietic Stem Cell Transplantation (HSCT) Market.

Hematopoietic Stem Cell Transplantation (HSCT) Market ShareYear-Over-Year Growthof Key Players in Promising Regions.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan)production, production value, consumption, consumption value, import and exportof Hematopoietic Stem Cell Transplantation (HSCT) market?

To Get Discount of Hematopoietic Stem Cell Transplantation (HSCT) Market:https://www.researchmoz.us/enquiry.php?type=D&repid=2276986

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

More:
Hematopoietic Stem Cell Transplantation (HSCT) Market Trends 2020: In-Depth Analysis of Industry Growth & Forecast Up To 2026 - Cole of Duty

Five years ago, we had only one treatment for sickle cell disease, a disease that should not be taken lightly.

This disease can be a pain-generating disease that actually affects all organs of the body. This can start at the heart, blood vessels, brain, joints, bones and also the lungs.

Sickle cell is due to a mutation of a tiny gene that leads to an unstable hemoglobin. The sickles in the hemoglobin, when stressed, deprive tissue from oxygen that can lead to what we call crisis.

Crisis starts with pain, but it can also lead to stroke, heart attack and limb loss. Sickle cell crisis is when the abnormal cell gets stuck in the small blood vessels.

Sickle cell disease affects approximately 100,000 people in the United States. For years, the only therapeutic option was Hydroxyurea. This drug has been in existence since 1984. We know that this drug works, since it has proved to be effective in increasing hemoglobin, reducing pain and acute chest syndrome.

This drug has also decreased the number of blood transfusions in patients who suffer from sickle cell disease. Unfortunately, Hydroxyurea is chemotherapy and requires close monitoring. This therapy works over time with each patient; therefore, not all patients will respond equally. Since Hydroxyurea was introduced, there has been a need for new treatments. For the past several years, more therapies have started to emerge.

The first notable drug that has been FDA approved in 2017, since Hydroxyurea, is L-glutamine (Endari). This drug works on the inflammatory part of the disease. It has also proved to decrease the number of pain crisis and lessen acute chest syndrome.

The second drug is Voxelotor. This drug is a once-daily pill that stabilizes the oxygenated hemoglobin. Trials have proved to make patients less anemic, but events are not necessarily less painful. More long-term studies are looking at this issue. This drug is available, and FDA approved, through an accelerated program.

The third drug is Crizanlizumab. This drug helps with the stickiness of the red blood cells against the sticky vessel wall. This is one of the detrimental aspects of this disease. A randomized study called SUSTAIN proved that this intravenous drug decreases the number of painful crisis. This drug was FDA approved through a breakthrough therapy program.

Lastly, there is gene therapy. This type of treatment consists of an auto stem cell transplant of a viral infected, anti-sticking hemoglobin. This therapy still requires chemotherapy to wipe out the bone marrow so that space can be made for the transplant. The results of this treatment have been very successful.

Many promising therapies are seeing the light and are changing the care of this complex disease so that patients with sickle cell disease can lead a semi-normal lifestyle.

Dr. Ziad Skaff is board certified in hematology and oncology. He serves as chief of staff of MUSC Health-Florence Medical Center and Medical Director of Oncology Services. Dr. Skaff is associated with MUSC Health Hematology & Oncology, located at 805 Pamplico Highway, Medical Pavilion A, Suite 315. To schedule an appointment, call 843-674-6460.

Read the original here:
Sickle cell treatment then and now - SCNow

Myeloproliferative disorders are disease of blood and bone marrow which have unknown cause and there are wide range of symptoms. The treatment of myeloproliferative disorders generally depends on the type and presence of symptoms. Myeloproliferative disorders is generally considered as clonal disorder which begins with one or more change in the DNA of a single stem cells in the bone marrow. The changes to the hematopoietic stem cell cause the cell to reproduce repeatedly, creating more abnormal stem cells and these abnormal cells become one or more types of blood cells. Myeloproliferative disorders gets worst with time as the number of extra blood cells build up in the bone marrow and bloodstream.

To remain ahead of your competitors, request for a sample [emailprotected] https://www.persistencemarketresearch.com/samples/27949

Emergence of new treatment for the myeloproliferative disorders and availability of novel drug drive the market for myeloproliferative disorders drugs market in the near future. Rising incidence of myeloproliferative disorders and presence of strong product pipeline spur the myeloproliferative disorders drugs market. Growing geriatric population, change in lifestyle and growing awareness among general population is expected to drive the market of myeloproliferative disorders in the forecast period.

Advancement in the treatment for oncology further expand the treatment option for myeloproliferative disorders. Various clinical trial undergoing for the treatment of myeloproliferative disorders which further drive the growth of the myeloproliferative disorders drugs market. However, high cost of drug and treatment along with the lack of awareness among the population in developing and under developed nations hinder the growth of myeloproliferative disorders drugs market.

The global myeloproliferative disorders drugs market is segmented on basis of Type, Drug Type, Distribution Channel, End User and Geography.

Improvement in the symptoms and reduction of in splenomegaly among patients receiving available therapy is expected to boost the market of myeloproliferative disorders. Development in new therapeutic drug and target therapy further drive the market growth of myeloproliferative disorders. Increased research and development and increased funding by the government towards the development of novel therapy spur the market growth. With the discovery of specific gene mutations in myeloproliferative disorders the market is expected to grow in the forecast period owing to increased adoption of new drugs and increased awareness along with the favorable reimbursement scenarios for the treatment of myeloproliferative disorders.

How the Coronavirus Threat has Taken Global Business into Uncharted Waters

The North America market holds the largest revenue share for myeloproliferative disorders drugs, due to presence of major pharmaceutical players undergoing various clinical innovation, government initiative and increase research and development funding for the Myeloproliferative disorders. Europe is expected to contribute for the second largest revenue share after North America in the global myeloproliferative disorders drugs market, owing to merging treatment option and development of oncology drug discovery and rising prevalence of myeloproliferative disorders.

Asia Pacific is expected to show rapid growth, due to increasing number of vascular surgeons and low cost of peripheral interventions. China is expected to register fast growth, due to significant increase in the number of innovative firm and research organization and increasing importance of pharmaceutical research & development activities and investments in research for developing new drugs. Latin America and Middle East & Africa are projected to exhibit sluggish growth in myeloproliferative disorders Drugs market, due to proper healthcare systems and adoption of new drug and therapy.

To receive extensive list of important regions, ask for TOC here @ https://www.persistencemarketresearch.com/toc/27949

Examples of some of the key manufacturer present in the global myeloproliferative disorders drugs market are,

Our unmatched research methodologies set us apart from our competitors. Heres why:

For in-depth competitive analysis, Check Pre-Book here @ https://www.persistencemarketresearch.com/checkout/27949

See the original post here:
Myeloproliferative Disorders Drugs Market Industry Trends and Developments Through 2026 - Cole of Duty

Stem cell banking or preservation is a combined process of extraction, processing and storage of stem cells, so that they may be used for treatment of various medical conditions in the future, when required. Stem cells have the amazing power to get transformed into any tissue or organ in the body. In recent days, stem cells are used to treat variety of life-threatening diseases such as blood and bone marrow diseases, blood cancers, and immune disorders among others.

The market of stem cell banking is anticipated to grow with a significant rate in the coming years, owing to factors such as, development of novel technologies for stem cell preservation and processing, and storage; growing awareness on the potential of stem cells for various therapeutic conditions. Moreover, increasing investments in stem cell research is also expected to propel the growth of the stem cell banking market across the globe. On other hand rising burden of major diseases and emerging economies are expected to offer significant growth opportunities for the players operating in stem cell banking market.

Get Sample PDF Copy athttps://www.theinsightpartners.com/sample/TIPBT00002082/

Key Points of the Report:

In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

1. Cordlife2. ViaCord (A Subsidiary of PerkinElmer)3. Cryo-Save AG4. StemCyte India Therapeutics Pvt. Ltd.5. Cryo-Cell International, Inc.6. SMART CELLS PLUS.7. Vita 348. LifeCell9. Global Cord Blood Corporation10. CBR Systems, Inc.

The Insight Partners has segmented the global Stem Cell Banking Market:

The source segment includes, placental stem cells (PSCS), dental pulp-derived stem cells (DPSCS), bone marrow-derived stem cells (BMSCS), adipose tissue-derived stem cells (ADSCS), human embryo-derived stem cells (HESCS), and other stem cell sources. Based on service type the market is segmented into, sample processing, sample analysis, sample preservation and storage, sample collection and transportation. Based on application, the market is segmented as, clinical applications, research applications, and personalized banking applications.

The report covers key developments in the Stem Cell Banking market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Stem Cell Banking market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Stem Cell Banking market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Stem Cell Banking market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Stem Cell Banking market in these regions.

Purchase this Report at:https://www.theinsightpartners.com/buy/TIPBT00002082/

About Us:The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Semiconductors, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Contact Person: Sameer JoshiPhone: +1-646-491-9876Email Id:[emailprotected]

See the rest here:
Stem Cell Banking Market to Witness Huge Growth in Coming Years 2020-2027 - Jewish Life News

Prophecy Market Insights Cell Therapy Manufacturing market research report provides a comprehensive, 360-degree analysis of the targeted market which helps stakeholders to identify the opportunities as well as challenges. The research report study offers keen competitive landscape analysis including key development trends, accurate quantitative and in-depth commentary insights, market dynamics, and key regional development status forecast 2020-2029. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21

An executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Cell Therapy Manufacturing market

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Segmentation Overview:

Cell Therapy ManufacturingMarket Key Companies:

harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

The Cell Therapy Manufacturing research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Cell Therapy Manufacturing market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Request [emailprotected] https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/21

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. This report is a must-read for investors, entrepreneurs, consultants, researchers, business strategists, and all those who have any kind of stake or are planning to foray into the Cell Therapy Manufacturing industry in any manner.

Key Questions Answered in Report:

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Read the original:
Market Analysis and Technological Opportunities of Cell Therapy Manufacturing Market till 2030 - Cole of Duty

The Hematopoietic Stem Cell Transplantation (HSCT) Market report includes overview, which interprets value chain structure, industrial environment, regional analysis, applications, market size, and forecast. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report provides an overall analysis of the market based on types, applications, regions, and for the forecast period from 2020 to 2026. It also offers investment opportunities and probable threats in the market based on an intelligent analysis.

This report focuses on the Global Hematopoietic Stem Cell Transplantation (HSCT) Market trends, future forecasts, growth opportunities, key end-user industries, and market players. The objectives of the study are to present the key developments of the market across the globe.

Get a PDF Copy of the Sample Report for Free @ https://www.upmarketresearch.com/home/requested_sample/30593

Key List Market Participants in the Market:Regen Biopharma IncChina Cord Blood CorpCBR Systems IncEscape Therapeutics IncCryo-Save AGLonza Group LtdPluristem Therapeutics IncViaCord I

By Types:AllogeneicAutologous

By Applications:Peripheral Blood Stem Cells Transplant (PBSCT)Bone Marrow Transplant (BMT)Cord Blood Transplant (CBT)

Scope of the Hematopoietic Stem Cell Transplantation (HSCT) Market Report:

Fill the Pre-order Inquiry Form for the Report @https://www.upmarketresearch.com/home/enquiry_before_buying/30593

By Regions:North America (The USA, Canada, and Mexico)Europe (Germany, France, the UK, and Rest of Europe)Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Latin America (Brazil and Rest of Latin America.)Middle East &Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa).

Report Answers Following Questions:

To Purchase This Report, Visit https://www.upmarketresearch.com/buy/hematopoietic-stem-cell-transplantation-market

Hematopoietic Stem Cell Transplantation (HSCT) Market Historic Data (2015-2019):

Hematopoietic Stem Cell Transplantation (HSCT) Market Forecast (2020-2026):

To Get this Report at an Incredible Discounts, Visit @ https://www.upmarketresearch.com/home/request_for_discount/30593

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Organization UpMarketResearchAddress 500 East E Street, Ontario, CA 91764, United States.

Read more from the original source:
Hematopoietic Stem Cell Transplantation (HSCT) Market Demand Analysis and Projected huge Growth by 2025 - Bulletin Line

Human Mesenchymal Stem Cells (hMSC) Market Sales 2020-2026

Worldwide Human Mesenchymal Stem Cells (hMSC) Market Report 2020-2026 is a systematic and insightful compilation of valuable evaluations of Human Mesenchymal Stem Cells (hMSC) market and relevant aspects. The report offers an in depth exploration of the market and its scope, trends, structure, production, profitability and maturity.

The precise evaluation of market size, share, revenue, sales volume, demand, and rate of growth involved within the report drive investors, industry experts, researchers, also as novice and well-established market players to grasp the general Human Mesenchymal Stem Cells (hMSC) market structure.

Report: calibreresearch.com/report/est-sample The Human Mesenchymal Stem Cells (hMSC) market report also delivers an in-depth analysis of the emerging industry trends along side the restraints, key players, and opportunities within the Human Mesenchymal Stem Cells (hMSC) market to supply worthwhile insights also as a gift scenario for generating right decision.

Moreover, the new report on the Human Mesenchymal Stem Cells (hMSC) industry covers the prominent vendors within the universal market alongside SWOT analysis, fiscal overview and major developments. The world Human Mesenchymal Stem Cells (hMSC) Market report is considered as a detailed investigation of the respective market that will provide key solutions for establishment of profit-driven business strategies.

It is helpful for offering details about futuristic Human Mesenchymal Stem Cells (hMSC) industry trends and in-depth assessment of the international industry. It permits you to determine remarkable challenges and risk factors alongside major opportunities available in the world Human Mesenchymal Stem Cells (hMSC) market.

This report also exhibits the whole historical and current status of the Human Mesenchymal Stem Cells (hMSC) Market worldly. Apart from this, the report on the Human Mesenchymal Stem Cells (hMSC) industry also represents the graphical representation of the upcoming Human Mesenchymal Stem Cells (hMSC) Market infrastructure and the Compound Annual Growth Rate (CAGR) in detail.

Report: calibreresearch.com/report/for-buying

The report on the Human Mesenchymal Stem Cells (hMSC) market is an exclusive and deep study which delivers a comprehensive overview of the industry contains the recent trends and future proportions of the Human Mesenchymal Stem Cells (hMSC) market in terms of product and services. Meanwhile, this report offers a professional research study on the Human Mesenchymal Stem Cells (hMSC) market so as to guage the remarkable vendors by calibrating all the relevant products or services to know the positioning of the key players within the Human Mesenchymal Stem Cells (hMSC) market worldly.

Leading companies reviewed in the Human Mesenchymal Stem Cells (hMSC) report are: PromoCell ThermoFisher KURABO Lifeline Cell Technology Merck The Human Mesenchymal Stem Cells (hMSC) Market report is segmented into following categories: The product segment of the report offers product market information such as demand, supply and market value of the product. The application of product in terms of USD value is represented in numerical and graphical format for all the major regional markets.

The Human Mesenchymal Stem Cells (hMSC) market report is segmented into Type by following categories; Umbilical Cord Matrix hMSC Bone Marrow hMSC Adipose Tissue hMSC Other The Human Mesenchymal Stem Cells (hMSC) market report is segmented into Application by following categories; Medical Application Research Other Applications

Report: calibreresearch.com/report/est-sample

The world Human Mesenchymal Stem Cells (hMSC) marketing research report offers an in depth summary of the foremost desirable factors and informative details about the universal industry. Moreover, the study provides an in-depth summary and forecast of the worldwide Human Mesenchymal Stem Cells (hMSC) market on the idea of several segments.

This report also delivers Human Mesenchymal Stem Cells (hMSC) market size and predicted estimations from the year 2020 to 2026 concerning various topological regions including Europe, North America, the center East and Africa, and South America. The research study on the Human Mesenchymal Stem Cells (hMSC) Market is a valuable source of guidance for world customers as it will rapidly fulfil their requirement and speed up their business growth.

It is an advantageous document for both existing industries manufactures including end-user industries, experts, managers, stakeholders and new entrants. We have designed this world Human Mesenchymal Stem Cells (hMSC) Market report in a deeply understandable format so that anyone can grasp each and every aspect related to the respective industry.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Go here to read the rest:
Human Mesenchymal Stem Cells (hMSC) Market investigated in the latest research - WhaTech Technology and Markets News

Celebrates milestone with registration of over 42,000 potential life savers in same time period in country

This World Blood Cancer Day, DKMS-BMST celebrates a milestone of registering over 42,000 potential lifesavers in a time period of one year in India. This group comprises of individuals who range from 18-50 years of age and have pledged to donate their blood stem cells to a blood cancer patient in need.

Focussed on helping patients with blood cancer and other blood disorders, DKMS-BMST has been able to save28unique lives in this period of one year including children diagnosed with blood cancer and other blood disorders like thalassemia.

Patients affected by blood cancer or thalassemia need a blood stem cell donation. Worldwide, only 30 per cent of them can find a match within their families and hence there is a dire need to find an unrelated donor. We started our operations in India last year with an intent to add potential blood stem cell donors of Indian ethnicity to the global database, so that patients (especially from this unique ethnicity) living in different parts of the world have a fair chance of finding a match and probably gain a second chance at life. We cannot thank enough, the people who are on-board and are helping us spread the word to add more and more people to this database,said Paul Patrick, CEO, DKMS BMST Foundation India.

Sharing his experience Mohd Saifulla, father to a 4-year-old thalassemia survivor said We went to multiple doctors trying to assess the problem our child had and thereafter to find a matching donor who could save her life. Receiving this transplant was the only chance of life for my daughter and we can never thank Debojyoti, a 28 year old software professional, enough, who donated his blood stem cells that matched our daughter. It is only because of organisations such as DKMS-BMST that people are coming forward to donate blood stem cells and save a life. My entire family is indebted to them for lifetime. Today my daughter is living a happy and healthy life and we are preparing to celebrate her fifth birthday this year that seemed like a dream to us up till a few years back.

Last year on World Blood Cancer Day, DKMS, one of the largest international blood stem cell donor centres in the world dedicated to the fight against blood cancer and blood disorders joined forces with Bangalore Medical Service Trust (BMST), a centre of excellence in blood banking, transfusion and immunohaematology adding India to the largest global repository of potential blood stem cell donors in the world. Every year, over 100,000 people in India are diagnosed with blood cancer or a blood disorder such asthalassemia or aplastic anaemia. Such life-threatening conditions can be managed by infusing a set of healthy blood stem cells from a suitable match. Since,ethnicity plays a crucial role in finding a matching donor, the ratio of potential blood stem cell donors from India needs to rise significantly, said Dr Latha Jagannathan, Director, DKMS BMST Foundation India.

Harsh, a blood stem cell donor registered with the foundation said,With very limited knowledge about blood stem cells I believed they were present only in the bone marrow and extracting them was a complex process. But to my surprise, the process is very similar to blood platelet donation. I strongly feel that anyone who is made aware that a simple process with zero complications can give you a chance to save a life will not hesitate from committing themselves towards the cause.

Capturing the challenges, the NGO faced in the country,Patrick said,We realised very early in India that a decision of this nature is not alone of the donor, but also involves his / her family. Hence, explaining the process, inculcating right awareness to break myths, updating people on the technological advances of blood stem cell donation and counselling them with medical experts has been our modus operandi in the country. Thus far, we have been able to conduct many physical drives to reach out to people urging them to register as potential donors. We plan to expand our reach to many more regions this year so that we are able to add potential donors from varied population groups in the country.

DKMS-BMST has organised over 1000donor registration drives in one year across various organisations such as corporates, educational institutes, hospitals and defence forces to spread awareness about blood stem cell donation and enroll more potential donors. Few names where physical drives have been conducted includes Mindtree, HSBC, HP enterprises, Christ University, RV College of Engineering, apart from public drives at Orion Mall Bengaluru, Lalbagh Botanical Garden etc.

In the current lockdown situation, the team is working tirelessly to ensure that patients whose donations were scheduled do not face any challenges and are organising awareness sessions through webinars and calling for registrations through the online portal:www.dkms-bmst.org/register.

Link:
DKMS-BMST Foundation India completes one year of operation in India - Express Healthcare

Myelofibrosis or osteomyelofibrosis is a myeloproliferative disorder which is characterized by proliferation of abnormal clone of hematopoietic stem cells. Myelofibrosis is a rare type of chronic leukemia which affects the blood forming function of the bone marrow tissue. National Institute of Health (NIH) has listed it as a rare disease as the prevalence of myelofibrosis in UK is as low as 0.5 cases per 100,000 population. The cause of myelofibrosis is the genetic mutation in bone marrow stem cells. The disorder is found to occur mainly in the people of age 50 or more and shows no symptoms at an early stage. The common symptoms associated with myelofibrosis include weakness, fatigue, anemia, splenomegaly (spleen enlargement) and gout. However, the disease progresses very slowly and 10% of the patients eventually develop acute myeloid leukemia. Treatment options for myelofibrosis are mainly to prevent the complications associated with low blood count and splenomegaly.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/11341

The global market for myelofibrosis treatment is expected to grow moderately due to low incidence of a disease. However, increasing incidence of genetic disorders, lifestyle up-gradation and rise in smoking population are the factors which can boost the growth of global myelofibrosis treatment market. The high cost of therapy will the growth of global myelofibrosis treatment market.

The global market for myelofibrosis treatment is segmented on basis of treatment type, end user and geography:

As myelofibrosis is considered as non-curable disease treatment options mainly depend on visible symptoms of a disease. Primary stages of the myelofibrosis are treated with supportive therapies such as chemotherapy and radiation therapy. However, there are serious unmet needs in myelofibrosis treatment market due to lack of disease modifying agents. Approval of JAK1/JAK2 inhibitor Ruxolitinib in 2011 is considered as a breakthrough in myelofibrosis treatment. Stem cell transplantation for the treatment of myelofibrosis also holds tremendous potential for market growth but high cost of therapy is foreseen to limits the growth of the segment.

On the basis of treatment type, the global myelofibrosis treatment market has been segmented into blood transfusion, chemotherapy, androgen therapy and stem cell or bone marrow transplantation. Chemotherapy segment is expected to contribute major share due to easy availability of chemotherapeutic agents. Ruxolitinib is the only chemotherapeutic agent approved by the USFDA specifically for the treatment of myelofibrosis, which will drive the global myelofibrosis treatment market over the forecast period.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/11341

Geographically, global myelofibrosis treatment market is segmented into five regions viz. North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Northe America is anticipated to lead the global myelofibrosis treatment market due to comparatively high prevalence of the disease in the region.

Some of the key market players in the global myelofibrosis treatment market are Incyte Corporation, Novartis AG, Celgene Corporation, Mylan Pharmaceuticals Ulc., Bristol-Myers Squibb Company, Eli Lilly and Company, Taro Pharmaceuticals Inc., AllCells LLC, Lonza Group Ltd., ATCC Inc. and others.

Read more:
Myelofibrosis Treatment Market to Create Lucrative Opportunities for Existing Companies as Well as New Players - Cole of Duty

On this page:BasicsComplementary TreatmentAlternative Treatment EffectivenessSide EffectsCancer Cure ScansDiet and Exercise

Youve seen the headlines about natural medicine trends, from yoga to supplements to diet and exercise fads. When it comes to cancer, you want to know what will help you safely regain your health during treatment and after. But there are loads of competing, sometimes-confusing info to sift through. What can you trust? Well, you can start with us here at HealthCentral: We went to the experts to learn all the science-based truth on complementary care for cancer.

First, lets clarify how cancer comes to be: Cancer occurs when abnormal cells anywhere in your body grow out of control, due to mutations in their DNA. Normal cells divide, age and die predictably, copying DNA as they go. Cancer cells, however, dont follow those rules. Rather than die off, they mutate, replicate, and form tumors.

Whats known as the primary site of your cancer is the spot where these cells start growing, and that organ or area determines the type of cancer you have. When cancerous cells journey through your blood or lymphatic system (the network of tissues and organs that flush out toxins, waste, and other undesirables), the areas they invade are metastatic sites.

Note that a cell can be abnormal without being cancerous (also known as malignant). It could be benign (not cancer), or precancerous or premalignant (likely to become cancer). Through screening and testing, docs can determine exactly what youre dealing with.

That depends on what kind of cancer you have, what stage its in, and other factors. Treatment can include:

Doctors often try more than one treatment, spaced out over weeks and months, as they gauge how your body responds. Your doc might even start you on multiple treatments at the same time.

Youve probably heard of complementary care. Or maybe you know it as alternative care. You know a bit of what these treatments might include (youre thinking meditation, herbs, and maybe yoga?). But did you know that while complementary and alternative care are often lumped together (as CAM, Complementary and Alternative Medicine), theyre not the same?

Complementary medicine is used in addition to conventional cancer care. It can include products, practices, and healthcare systems outside of mainstream medicine. These methods dont cure cancer, but work in conjunction with conventional cancer treatments to help in a variety of ways, including pain management and emotional support. Many complementary medicine practices can be considered evidence-based medicine (scientifically studied in randomized controlled trials, the highest level of evidence that guides cancer care).

When complementary medicine works harmoniously with conventional medicine, its an approach known as integrative medicine, or integrated care, where physicians treat you holisticallymeaning caring for you as a whole patient, taking into account all facets of your cancer experience. These can include:

When integrative medicine is administered to treat cancer, its known as integrative oncology, a patient-centered, evidence-informed field of cancer care. It may include:

Alternative medicine, in contrast, is used in place of conventional medicine. Rather than going hand-in-hand with, say surgery and chemo, alternative medicine is done instead of those evidence-based cancer treatments.

A quick note: before you try any new approach during (and after) your cancer treatment journey, make sure to discuss it with your doctor.

If youve used or are considering using complementary medicine as a cancer patient, youre not alonea national survey found that 65% of respondents whod been diagnosed with cancer had used some form of it.

Theres good reason to explore complementary care if you have cancer. It can be part of your supportive carehelping where you need it, like soothing and calming your mind and body as you go through this challenging time. Indeed, research suggests that complementary medicine can assist by:

There are easily hundreds of complementary treatments for cancer, so weve selected a small sample to discuss here. Possibilities include:

Acupuncture: Theres substantial evidence that this ancient Chinese practice of using sterile needles to stimulate different areas of the body can help manage cancer treatment-related nausea and vomiting. It may also help relieve cancer pain and other symptoms, but theres not enough evidence yet to support that.

Herbs: Ginger, for instance, has been shown to help control nausea from chemotherapy when used with conventional anti-nausea medications. Just keep in mind that any supplements you consume can change your body physiologicallynothing you ingest is without the potential for adverse effects. For instance, herbs can impact blood sugar levels and the bloods ability to clot.

Massage therapy: Sure, it feels sublime, and it turns out to have additional benefits too: research suggests that massage therapy can help relieve some cancer symptoms including:

Just be careful not to have deep tissue massage near surgery sites, tumors, or any medical devices. And always tell your therapist about your cancer diagnosis.

Meditation: Mindfulness-based meditation has been shown to improve quality of life during treatment. How? Studies of cancer patients have revealed the following happiness-boosting benefits:

Supplements: Herbal supplements for cancer could potentially help manage side effects like nausea and vomiting, pain, and fatigue, but more scientific evidence is required to make safe decisions about the use of these supplements.

Yoga: Preliminary data of this ancient mind/body practice from India suggests that those who do yoga could see improvements in these areas:

Another benefit: It might help lessen fatigue in breast cancer patients and survivors. More study into the myriad benefits of yoga is needed.

Other approaches: These include hypnosis, relaxation therapy, and biofeedback, all of which might help manage cancer symptoms and treatment side effects, based on study results.

One thing to note about all of these approaches: they might not be covered by your health insurance. According to the American Cancer Society, major insurers, including Blue Cross and Medicare, are starting to cover some complementary treatments. On the list above, acupuncture is most commonly covered. Contact your insurer to see what complementary treatments, if any, are paid for. They might be able to direct you to local providers who are covered under your plan.

When the treatments we discussed earlier (and the hundreds of others that are offered) are used in place of conventional medicine, its known as an alternative treatment. Nearly 40%, or 4 out of 10 Americans, believes that cancer can be cured by alternative treatments, a 2018 survey of cancer patients and people without cancer, found. However, while research shows that complementary medicine can play an important role in conventional cancer medicine, the same hasnt been readily found for alternative treatment.

Case in point: in 2009, the Society for Integrative Oncology (the leading international organization for healthcare professionals and researchers working in the field of complementary therapies in cancer care) published guidelines for healthcare professionals when using complementary medicine.

The org reminded healthcare professionals and patients that unproven cancer treatment methods shouldnt be used in place of conventional options because delaying cancer treatment thats evidence-based and shown to work reduces the chance of remission/cure for cancer patients.

Its important to talk with your healthcare professionals about the risks of using alternative therapies so you can make an informed decision about whats best for your health.

There are definite side effects with CAM. You might think that because something is natural, its safe. But this isnt always the case. Arsenic is natural, for instance, but you wouldnt want to start taking it in large doses.

Another example: Chemotherapy has a multitude of side effects because it destroys both cancerous cells and healthy cells. Its been cited by many as harmful because its made from chemicals. But did you know, some forms of chemo come from nature? Three drugs (Vincristine, Vinblastine, and Vinorelbine) are derived from plant alkaloids and are made from the periwinkle plant (Catharanthus Rosea). Chemo drugs called taxanes (Paclitaxel and Docetaxel) come from the bark of the Pacific Yew tree (Taxus).

Know too that just because something is sold, doesnt mean its been vetted or approved for usefor safety or qualityby the U.S. Food and Drug Administration (FDA). The FDA doesnt regulate vitamins and supplements, so the onus is on us to do our best to source safe, trustworthy products.

Its vital to tell your cancer healthcare team about every treatment and therapy youre using for your cancer, whether its receiving acupuncture for nausea, going to the chiropractor for pain, adding St. Johns Wort to your supplement regime to help manage depression, or getting a massage to feel better.

If youre reluctant to be open with your doc, youre not alone: 29% of cancer patients did not disclose their CAM practices to their providers, according to one study. Secret-keeping could be downright dangerous. Lets use these four seemingly innocuous examples to illustrate why:

Being open with your doc--both before you start a complementary treatment and while youre on it--is key to helping it complement, rather than detract, from the conventional care youre receiving.

When you have cancer, you of course want a cure (as quickly and painlessly as possible, please). But that desire can leave you vulnerable to fake claims, especially in the alternative medicine space. Both the FDA and the Federal Trade Commission (FTC) regularly warn the public about fraudulent cancer treatments.

It can be hard to spot the signs of snake oil. Without a medical degree, how can you be wise to empty promises? Youll often see the same language used in cancer CAM scams, according to the FDA. These phrases should raise a red flag that a treatment is just too good to be true:

Heres how you can protect yourself while receiving evidence-based integrated care:

You might be wondering now: with all this talk of complementary and alternative medicine, what about food? And diet? And exercise? What role does it play in all this? Is there a cancer diet that could be a complementary treatment?

Turns out, theres a strong body of evidence that a healthy diet and regular physical activity are associated with a reduced risk of cancer. The scientific literature links nutrition to cancer prevention based on specific physiologic pathways, including reducing inflammation, regulating hormones, and preventing oxidative stress. Even after a cancer diagnosis, by making smart choices about what they put on their plate, patients can:

Food has power. To wield it, the American Institute for Cancer Research and American Cancer Society recommends you:

As for physical activity? While you should talk to your healthcare team about what kind and amount of exercise is safe during treatment, The American College of Sports Medicine (ACSM) has issued guidelines for physical activity for cancer survivors, suggesting 150-300 minutes per week of moderate to vigorous physical activity. Exercise is a real magic pill, helping to:

As you can imagine, all of these benefits that come along with being active are particularly important when youre trying to put cancer behind you. Resistance training, in particular, has been proven to improve:

Exercise, like so many CAM options, can help you both feel stronger and respond to treatment better. Just as with other types of complementary treatments, youll want to talk to your doc about how to integrate it, so you can reap the maximum benefits both from your lifestyle changes and your conventional cancer treatment.

Researchers have found that a healthy diet is associated with a reduced risk of cancer. Even if you have cancer, it can help lessen the impact of side effects and improve your quality of life. Studies link nutrition to cancer prevention based on specific physiologic pathways, including reducing inflammation, regulating hormones, and preventing oxidative stress. All to say that food matters.

Heres the thing: there are therapies that can help you go into remission (the period when your signs and symptoms of cancer are reduced). And some healthcare professionals consider cancer cured if it hasnt returned after five years (also called complete remission). Treatments that achieve a complete remission/cure can include therapies that come from a natural source, like some forms of chemo, which are derived from plant alkaloids. But anyone promising a natural cure for cancer that doesnt have evidence to back up that claim is likely pedaling bunk.

As weve discussed, herbs can be excellent complementary treatment in oncology for things like nausea, but any claim of curing cancer should be tempered by evidence-based medicine results (meaning, proof to back up those claims).

The American Academy of Dermatology warns that black salve isnt as safe as you might think, stating that it has never been proven to work. An article on the AADs website cites reports of bad outcomes for people who tried to treat their cancer (including melanoma) using black salve. The U.S. Food and Drug Administration (FDA) warns against products that are touted as cures for cancer without evidence: The FDA urges consumers to steer clear of these potentially unsafe and unproven products and to always discuss cancer treatment options with their licensed health care provider.

See original here:
Alternative and Complementary Treatments for Cancer - HealthCentral.com

COVID-19 impact will also be included and considered for forecast.

Global Cell Harvesting System Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Cell Harvesting System Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=153&RequestType=Sample

Cell Harvesting System Market: Increase in healthcare facilities and increase in bone marrow transplantation are key drivers for the Global Cell Harvesting System Market.

The global cell harvesting systems market size was valued USD 3533.27 Million in 2017 and is expected to grow at a CAGR of 14.01% over the forecast period.

Cell harvesting is a system which is used to cultivate, regenerate, transplant and repair the damages organs with the healthy one. Cell harvesting is one of the important parts of biopharmaceutical industry which directly relates with the quality of product. Stem cell harvesting also helps in the treatment of various diseases such as cancer, autoimmune disease, anemia and others. So, during the study of Global Cell Harvesting System market, we have considered Cell Harvesting System to analyze the market.

Global Cell Harvesting System Market report is segmented on the technique type, application type, end user type and by regional & country level. Based upon technique type, global Cell Harvesting System Market is classified as Altered Nuclear Transfer and Blastomere Extraction. Based upon Application type, global Cell Harvesting System Market is classified as Bone Marrow, Peripheral Blood, Umbilical Cord Blood, and Adipose Tissue. Based upon end users, global Cell Harvesting System Market is classified as Research Centers, Academics Institutes, Diagnostic Labs, and Hospitals.

The regions covered in this Cell Harvesting System Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Cell Harvesting System is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Cell Harvesting System Market Reports

Global Cell Harvesting System market report covers prominent players like Tomtec, Bertin Technologies, PerkinElmer Inc., TERUMO BCT, INC., SP Scienceware, hynoDent AG, Avita Medical, BRAND GMBH Teleflex Incorporated., Argos Technologies, Inc., Thomas Scientific, Arthrex, Inc. and others.

Global Cell Harvesting System Market Dynamics

The commercialization and growth of global Cell Harvesting System market over the past 25 years has been highly impactful. Bone marrow transplantation is one of the major factors driving the growth of cell harvesting system over the forecast period. Due to the increase in blood cancer it has raised the demand for bone marrow transplantation which in turn increased the demand for cell harvesting system. As per The Leukemia & Lymphoma Society report 2018, an estimated combined total of 174,250 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2018. There is also an increase in awareness about stem cells and its advantages which are helpful in the treatment of various disorders. Furthermore, various technological advancement have also increase the new and better technologies with better results are expected to promote the growth of cell harvesting system market over the forecast period. However, High cost, lack of reimbursement policies, immune rejection and others are the various factors which are expected to hamper the growth of cell harvesting system market over the forecast period.

Global Cell Harvesting System Market Regional Analysis

North America dominates the market with highest market share which is closely followed by the Europe over the forecast period. Due to the increased prevalence of leukemia, lymphoma and others coupled with increased healthcare facilities. As per The Leukemia & Lymphoma Society 2018 report, new cases of leukemia, lymphoma and myeloma are expected to account for 10 percent of the estimated 1,735,350 new cancer cases diagnosed in the US in 2018. Asia Pacific is expected to be the third largest and fastest growing region over the forecast period. Due to various technological advancements, increase in awareness among people and others are expected to support the growth of cell harvesting system market over the forecast period. Furthermore, Increase in healthcare facilities in the developing economies such as India, China and others are expected to fuel the growth of cell harvesting system market. Latin America, Middle East and Africa and expected to develop at a considerable rate over the forecast period.

Key Benefits for Global Cell Harvesting System Market Reports

Global Cell Harvesting System market report covers in depth historical and forecast analysis.Global Cell Harvesting System Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Global Cell Harvesting System Market report helps to identify opportunities in market place.Global Cell Harvesting System Market report covers extensive analysis of emerging trends and competitive landscape.

By Techniques Type:

Altered Nuclear TransferBlastomere Extraction

By Application:

Bone MarrowPeripheral BloodUmbilical Cord BloodAdipose Tissue

By End User:

Research CentersAcademics InstitutesDiagnostic LabsHospitals

By Region

North AmericaU.S.CanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilMexicoThe Middle East and AfricaGCCAfricaRest of Middle East and Africa

Cell Harvesting System Market Key PlayersTomtecBertin TechnologiesPerkinElmer Inc.TERUMO BCT, INC.SP SciencewarehynoDent AGAvita MedicalBRAND GMBHTeleflex Incorporated.Argos Technologies, Inc.Thomas ScientificArthrex, Inc.

Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=153&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Cell Harvesting System Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Cell Harvesting System Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Cell Harvesting System Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Cell Harvesting System Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Cell Harvesting System Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Cell Harvesting System Market.

Market Forecast: Here, the report offers a complete forecast of the Global Cell Harvesting System Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

Top Trending Reports:

Here is the original post:
Covid 19 Outbreak Cell Harvesting System Market 2020 Product Type, Applications/end user, Key Players and Geographical Regions 2026 - Jewish Life...

People usually volunteer to donate stem cells for an allogeneic transplant either because they have a loved one or friend who needs a match or because they want to help people. Some people give their stem cells so they can get them back later if they need an autologous transplant.

People who want to donate stem cells or join a volunteer registry can speak with a health care provider or contact the National Marrow Donor Program to find the nearest donor center. Potential donors are asked questions to make sure they are healthy enough to donate and dont pose a risk of infection to the recipient. For more information about donor eligibility guidelines, contact Be the Match or the donor center in your area.

Be the Match (formerly the National Marrow Donor Program)Toll-free number: 1-800-MARROW-2 (1-800-627-7692)Website: http://www.bethematch.org

A simple blood test is done to learn the potential donors HLA type. There may be a one-time, tax-deductible fee of about $75 to $100 for this test. People who join a volunteer donor registry will most likely have their tissue type kept on file until they reach age 60.

Pregnant women who want to donate their babys cord blood should make arrangements for it early in the pregnancy, at least before the third trimester. Donation is safe, free, and does not affect the birth process.

If a possible stem cell donor is found to be a good match for a recipient, steps are taken to teach the donor about the transplant process and make sure he or she is making an informed decision. If a person decides to donate, a consent form must be signed after the risks of donating are fully discussed. The donor is not pressured to take part. Its always a choice.

If a person decides to donate, a medical exam and blood tests will be done to make sure the donor is in good health.

Stem cells may be collected from these 3 different sources:

Each method of collection is explained here.

This process is often called bone marrow harvest. Its done in an operating room, while the donor is under general anesthesia (given medicine to put them into a deep sleep so they dont feel pain). The marrow cells are taken from the back of the pelvic (hip) bone. The donor lies face down, and a large needle is put through the skin and into the back of the hip bone. Its pushed through the bone to the center and the thick, liquid marrow is pulled out through the needle. This is repeated several times until enough marrow has been taken out (harvested). The amount taken depends on the donors weight. Often, about 10% of the donors marrow, or about 2 pints, are collected. This takes about 1 to 2 hours. The body will replace these cells within 4 to 6 weeks. If blood was taken from the donor before the marrow donation, its often given back to the donor at this time.

After the bone marrow is harvested, the donor is taken to the recovery room while the anesthesia wears off. The donor may then be taken to a hospital room and watched until fully alert and able to eat and drink. In most cases, the donor is able to leave the hospital within a few hours or by the next morning.

The donor may have soreness, bruising, and aching at the back of the hips and lower back for a few days. Over-the-counter pain medications or nonsteroidal anti-inflammatory drugs are helpful. Some people may feel tired or weak, and have trouble walking for a few days. The donor might be told to take iron supplements until the number of red blood cells returns to normal. Most donors get back to their usual activities in 2 to 3 days. But it could take 2 or 3 weeks before they feel completely back to normal.

There arent many risks for donors and serious complications are rare. But bone marrow donation is a surgical procedure. Rare complications could include anesthesia reactions, infection, nerve or muscle damage, transfusion reactions (if a blood transfusion of someone elses blood is needed this doesnt happen if you get your own blood), or injury at the needle insertion sites. Problems such as sore throat or nausea may be caused by anesthesia.

Allogeneic stem cell donors do not have to pay for the harvesting because the recipients insurance company usually covers the cost. Even so, be sure to ask about insurance coverage before you decide to have the bone marrow harvest done.

Once the cells are collected, they are filtered through fine mesh screens. This prevents bone or fat particles from being given to the recipient. For an allogeneic or syngeneic transplant, the cells may be given to the recipient through a vein soon after they are harvested. Sometimes theyre frozen, for example, if the donor lives far away from the recipient.

For several days before starting the donation process, the donor is given a daily injection (shot) of a drug that causes the bone marrow to make and release a lot of stem cells into the blood. Filgrastim can cause some side effects, the most common being bone pain and headaches. These may be helped by over-the-counter pain medications or nonsteroidal anti-inflammatory drugs. Nausea, sleeping problems, low-grade (mild) fevers, and tiredness are other possible effects. These go away once the injections are finished and collection is completed.

After the shots, blood is removed through a catheter (a thin, flexible plastic tube) thats put in a large vein in the arm. Its then cycled through a machine that separates the stem cells from the other blood cells. The stem cells are kept while the rest of the blood is returned to the donor, often through the same catheter. (In some cases, a catheter may be put in each arm one takes out blood and the other puts it back.) This process is called apheresis. It takes about 2 to 4 hours and is done as an outpatient procedure. Often the process needs to be repeated daily for a few days, until enough stem cells have been collected.

Possible side effects of the catheter can include trouble placing the catheter in the vein, blockage of the catheter, or infection of the catheter or at the area where it enters the vein. Blood clots are another possible side effect. During the apheresis procedure, donors may have problems caused by low calcium levels from the anti-coagulant drug used to keep the blood from clotting in the machine. These can include feeling lightheaded or tingly, and having chills or muscle cramps. These go away after donation is complete, but may be treated by giving the donor calcium supplements.

The process of donating cells for yourself (autologous stem cell donation) is pretty much the same as when someone donates them for someone else (allogeneic donation). Its just that in autologous stem cell donation the donor is also the recipient, giving stem cells for his or her own use later on. For some people, there are a few differences. For instance, sometimes chemotherapy (chemo) is given before the growth factor drug is used to tell the body to make stem cells. Also, sometimes it can be hard to get enough stem cells from a person with cancer. Even after several days of apheresis, there may not be enough for the transplant. This is more likely to be a problem if the patient has had certain kinds of chemo in the past, or if they have an illness that affects their bone marrow.

Cord blood is the blood thats left in the placenta and umbilical cord after a baby is born. Collecting it does not pose any health risk to the infant or the mother. Cord blood transplants use blood that would otherwise be thrown away. After the umbilical cord is clamped and cut, the placenta and umbilical cord are cleaned. The cord blood is put into a sterile container, mixed with a preservative, and frozen until needed.

Some parents choose to donate their infants cord blood to a public blood bank, so that it may be used by anyone who needs it. Many hospitals collect cord blood for donation, which makes it easier for parents to donate. Parents can donate their newborns cord blood to volunteer or public cord blood banks at no cost. For more about donating your newborns cord blood, call 1-800-MARROW2 (1-800-627-7692) or visit Be the Match.

Other parents store their newborns cord blood in private cord blood banks just in case the child or a close relative needs it someday. If you want to donate or bank (save) your childs cord blood, youll need to arrange it before the baby is born. Some banks require you to set it up before the 28th week of pregnancy, although others accept later setups. Among other things, youll be asked to answer health questions and sign a consent form.

Parents may want to bank their childs cord blood if the family has a history of diseases that may benefit from stem cell transplant. There are several private companies offer this service. But here are some things to think about:

More information on private family cord blood banking can be found at the Parents Guide to Cord Blood Foundation. You can visit their website at http://www.parentsguidecordblood.org.

Continued here:
Donating Stem Cells and Bone Marrow

Bone marrowaspiration and trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.

Get Access to sample pages @https://www.trendsmarketresearch.com/report/sample/3184

The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.Europe and North America spearheaded the market as of 2016, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.

In 2016, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy.

Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.

Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others

Covid 19 ImpactAnalysis@https://www.trendsmarketresearch.com/report/covid-19-analysis/3184

Read this article:
Bone Marrow Processing System Market Incisive Insights Regarding Major Regions, Key Players And Opportunities Up To 2025 - Kentucky Journal 24

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Know the Growth Opportunities in Emerging Markets

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

The regional analysis covers:

Order this Report TOC for Detailed Statistics

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1787<ype=S

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Continued here:
Stem Cell Therapy Market Analysis and Demand 2017 2025 - Cole of Duty

Mesenchymal Stem Cells Market Trends by Manufacturers, States, Type and Application, Forecast to 2019 2027

Global Mesenchymal Stem Cells Market: Snapshot

The increasing use of mesenchymal stem cells (MSCs) for the treatment of diseases and disabilities of the growing aging population is having a positive influence on the global mesenchymal stem cells market. Mesenchymal stem cells are adult stem cells that are of various types such as adipocytes, osteocytes, monocytes, and chondrocytes.

The main function of mesenchymal stem cells is to replace or repair damaged tissue.

Report Overview @www.transparencymarketresearch.com/mesencharket.html

Mesenchymal stem cells are multipotent, i.e. they can produce more than one type of specialized cells.

These specialized cells have their own distinguishing shapes, structures, and functions, with each of them belonging to a particular tissue.

Mesenchymal stem cells are traditionally found in the bone marrow. However, these cells can also be separated from other tissues such as cord blood, fallopian tube, peripheral blood, and fetal liver and lung.

Mesenchymal stem cells have long thin cell bodies containing a large nucleus. MSCs have enormous capacity for renewal keeping multipotency.

Due to these virtues, mesenchymal stem cells have huge therapeutic capacity for tissue repair.

Get Brochure of the Report @www.transparencymarketresearch.com/sample/p_id=26735

Mesenchymal stem cells can differentiate into a number of cell types that belong to our skeletal tissues that include cartilage, bone, and fat. Research is underway to discover if mesenchymal stem cells can be used to treat bone and cartilage diseases.

Scientists are also exploring the possibility if mesenchymal stem cells differentiate into other type of cells apart from skeletal tissues. This includes nerve cells, liver cells, heart muscle cells, and endothelial cells.

This will lead to mesenchymal stem cells to be used to treat other diseases.

Stem cells are specialized cells which have the capability of renewing themselves through cell division and differentiate into multi-lineage cells. Mesenchymal stem cells (MSCs) are non- hematopoietic, multipotent adult stem cells which can be isolated from bone marrow, cord blood, fat tissue, peripheral blood, fallopian tube, and fetal liver and lung tissue.

Request For Covid19 Impact Analysis http://www.transparencymarketresearch.com/sample/p_id=26735

Mesenchymal stem cells have the capacity to differentiate into mesodermal lineages, such as chondrocytes, adipocytes, and osteocytes, and non-mesodermal lineages such as ectodermal (neurocytes) and endodermal lineages (hepatocytes). These stem cells have specific features such as multilineage potential, secretion of anti-inflammatory molecules, and immunomodulation.

These cells have emerged as promising therapeutic agents for regenerating skeletal tissues such as damaged bone and cartilage tissues and treatment of chronic diseases owing to their specific features.

The global mesenchymal stem cells market is expected to be driven by the increasing clinical application of mesenchymal stem cells for the treatment of chronic diseases, bone and cartilage diseases, and autoimmune diseases. Studies have shown that these stem cells enhance the angiogenesis in myocardium and allow the reduction of myocardial fibrotic area.

The pre-clinical studies for using mesenchymal stem cells in treatment of cardiovascular diseases, liver diseases, and cancer are projected to create new market opportunities for mesenchymal stem cells. Mesenchymal stem cells also produce anti-inflammatory molecules which modulate humoral and cellular immune responses.

Features of these stem cells such as ease of isolation, regenerative potential, and immunoregulatory, the mesenchymal stem cell therapy has emerged as a promising tool for the treatment of chronic diseases, degenerative, inflammatory, and autoimmune diseases.

Pre Book Now @www.transparencymarketresearch.com/checkoump;ltype=S

Clinical studies are exploring MSCs for various conditions such as orthopedic injuries, graft versus host disease following bone marrow transplantation, and genetic modification of MSCs to overexpress antitumor genes for use as anticancer therapy, which are exhibiting new opportunities in therapeutic area. However, the mesenchymal stem cell research studies are tedious, lengthy, and complex.

In some cases, due to some adverse effects transplanted mesenchymal stem cells rapidly removed from the body which limits use of stem cells in therapeutic treatments. The conflicting results and regulatory compliances for approvals may also hamper the growth of this market.

The global mesenchymal stem cells market is segmented on the basis of source of isolation, end-user, and region. Stem cells are isolated from the bone marrow, peripheral blood, lung tissue, umbilical cord blood, amniotic fluids, adipose tissues, and synovial tissues.

Traditionally the MSCs were isolated from bone marrow aspiration which is associated with risk of infection and painful for the patient. The MSCs from adipose tissues are usually isolated from the biological material generated during liposuction, lipectomy procedures by using collagenase enzymatic digestion followed by centrifugation and washing.

In terms of end-user, the market is segmented into clinical research organizations, biotechnological companies, medical research institutes, and hospitals.

Read our Case study at :www.transparencymarketresearch.com/casestug-start-up

Geographically, the global mesenchymal stent cells market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to continue its dominance in terms of market share during the forecast period owing to high R&D expenditure, availability of advanced research facilities and skilled professionals, and government initiatives.

Europe is the second largest market after North America. The Asia Pacific market is projected to expand at a high CAGR during the forecast period due to increased R&D budgets in Japan, China, and India.

Key global players operating in the mesenchymal stem cells market include R&D Systems, Inc., Cell Applications, Inc., Axol Bioscience Ltd., Cyagen Biosciences Inc., Cytori Therapeutics Inc., Stemcelltechnologies Inc., BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc., and Celprogen, Inc.

This email address is being protected from spambots. You need JavaScript enabled to view it.

See original here:
Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 - WhaTech Technology and Markets News

The Phase 2 study will assess the safety and efficacy of Longeveron's stem cell treatment under Japan's accelerated regulatory pathway for regenerative medicine.

MIAMI, June 1, 2020 /PRNewswire/ --Longeveron LLC announced today that Japan's Pharmaceutical and Medical Devices Agency (PMDA) (the Japanese agency akin to the United States' Food & Drug Administration) approved a Clinical Trial Notification (CTN) application (akin to an Investigational New Drug Application or "IND" in the US regulatory system), approving the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of Longeveron's Mesenchymal Stem Cells (LMSCs) for the treatment of Aging Frailty in Japanese patients. This is another key milestone for Longeveron's Aging Frailty program, which includes two ongoing Phase 2 clinical trials in the U.S.

"We are extremely pleased to achieve this significant milestone," said Geoff Green, President of Longeveron."This study is designed to determine whether the transplant of donor-derived mesenchymal stem cells can improve healthspan in mild to moderately frail patients, thereby improving functionality and potentially lowering their risk of disability, and dependence on others for care."

Aging Frailty is a common, but reversible, life-threatening geriatric condition affecting millions of Japanese over the age of 65.Frail individuals are vulnerable to adverse health outcomes compared to their age-matched peers despite sharing similar comorbidities and demographics.Clinically, frailty manifests as a combination of symptoms that may include loss of muscle and decreased strength, slowed walking (sarcopenia), lower activity and energy levels, poor endurance, nutritional deficiencies, weight loss and fatigue.Collectively, these lead to overall decline in functionality, and increased risk of disability, dependency, and death.

"The biology of frailty is complex, and includes diminished stem cell activity, reduced ability to repair and regenerate tissue, and immunosenescence (deterioration of the immune system) and chronic systemic inflammation," said Dr. Anthony Oliva, Senior Scientist at Longeveron. "LMSCs have multiple mechanisms of action that can potentially address all of these issues, and thus make them extremely attractive as a therapeutic candidate for the unmet medical need of Aging Frailty."

The planned study is an investigator-initiated, randomized, double-blind, placebo-controlled design,and will be conducted at Juntendo University Hospital (Tokyo) and Japan's National Center for Geriatrics and Gerontology (NCGG) in Nagoya.The study's Principal Investigator, Dr. Hidenori Arai, President of the NCGG, commented that "Japan has one of the oldest and fastest aging societies in the world, with nearly 30% of Japan's citizens over the age of 65.Preventing and reversing functional decline associated with frailty is one of the nation's top priorities, and Longeveron's regenerative medicine approach is an exciting and innovative potential therapeutic option.With the disproportionate infection and mortality rate of older people with COVID-19 and Influenza infection, it is critically important to rapidly test treatments that may be effective."

In Japan, the "Pharmaceutical and Medical Device Act" and the "Act on the Safety of Regenerative Medicine" came into effect in 2014. Under this system, a "Time-limited Conditional Approval" option exists, which allows a manufacturer to conditionally sell regenerative medicine products while proceeding with its Phase 3 clinical trial.

Longeveron's Aging Frailty Research Program

Longeveron sponsors the most extensive and advanced Aging Frailty clinical research program in the world, with more than 200 patients treated with LMSCs worldwide.In the U.S., two clinical trials are currently ongoing:

About LMSCs

Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) is a regenerative medicine product sourced from the bone marrow of young healthy adult donors.LMSCs are culture expanded under the FDA's current good manufacturing practices (cGMP) to high standards, and maintained as individual "off-the-shelf" doses.

About Longeveron LLC

Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014. Longeveron's mission is to provide biological solutions for aging-related diseases and life-threatening conditions, and is dedicated to developing safe and effective cell-based therapeutics for unmet medical needs such as Aging Frailty, the Metabolic Syndrome, Alzheimer's Disease, Acute Respiratory Distress Syndrome (ARDS) from COVID-19 infection, and congenital heart defects in children (hypoplastic left heart syndrome).

For information please contact:

Paul Lehr, JDplehr@longeveron.com305-338-6257

Related Images

longeveron.png LONGEVERON Longeveron - Biological Solutions for Aging

Related Links

Website

View original content to download multimedia:http://www.prnewswire.com/news-releases/longeveron-announces-japanese-approval-of-clinical-trial-for-treatment-of-aging-frailty-with-longeverons-stem-cells-301068215.html

SOURCE LONGEVERON

Read more from the original source:
Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells - Yahoo Finance

DetailsCategory: DNA RNA and CellsPublished on Monday, 01 June 2020 18:32Hits: 165

The Phase 2 study will assess the safety and efficacy of Longeveron's stem cell treatment under Japan's accelerated regulatory pathway for regenerative medicine.

MIAMI, FL, USA I June 1, 2020 I Longeveron LLC announced today that Japan's Pharmaceutical and Medical Devices Agency (PMDA) (the Japanese agency akin to the United States' Food & Drug Administration) approved a Clinical Trial Notification (CTN) application (akin to an Investigational New Drug Application or "IND" in the US regulatory system), approving the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of Longeveron's Mesenchymal Stem Cells (LMSCs) for the treatment of Aging Frailty in Japanese patients. This is another key milestone for Longeveron's Aging Frailty program, which includes two ongoing Phase 2 clinical trials in the U.S.

"We are extremely pleased to achieve this significant milestone," said Geoff Green, President of Longeveron."This study is designed to determine whether the transplant of donor-derived mesenchymal stem cells can improve healthspan in mild to moderately frail patients, thereby improving functionality and potentially lowering their risk of disability, and dependence on others for care."

Aging Frailty is a common, but reversible, life-threatening geriatric condition affecting millions of Japanese over the age of 65.Frail individuals are vulnerable to adverse health outcomes compared to their age-matched peers despite sharing similar comorbidities and demographics.Clinically, frailty manifests as a combination of symptoms that may include loss of muscle and decreased strength, slowed walking (sarcopenia), lower activity and energy levels, poor endurance, nutritional deficiencies, weight loss and fatigue.Collectively, these lead to overall decline in functionality, and increased risk of disability, dependency, and death.

"The biology of frailty is complex, and includes diminished stem cell activity, reduced ability to repair and regenerate tissue, and immunosenescence (deterioration of the immune system) and chronic systemic inflammation," said Dr. Anthony Oliva, Senior Scientist at Longeveron. "LMSCs have multiple mechanisms of action that can potentially address all of these issues, and thus make them extremely attractive as a therapeutic candidate for the unmet medical need of Aging Frailty."

The planned study is an investigator-initiated, randomized, double-blind, placebo-controlled design,and will be conducted at Juntendo University Hospital (Tokyo) and Japan's National Center for Geriatrics and Gerontology (NCGG) in Nagoya.The study's Principal Investigator, Dr. Hidenori Arai, President of the NCGG, commented that "Japan has one of the oldest and fastest aging societies in the world, with nearly 30% of Japan's citizens over the age of 65.Preventing and reversing functional decline associated with frailty is one of the nation's top priorities, and Longeveron's regenerative medicine approach is an exciting and innovative potential therapeutic option.With the disproportionate infection and mortality rate of older people with COVID-19 and Influenza infection, it is critically important to rapidly test treatments that may be effective."

In Japan, the "Pharmaceutical and Medical Device Act" and the "Act on the Safety of Regenerative Medicine" came into effect in 2014. Under this system, a "Time-limited Conditional Approval" option exists, which allows a manufacturer to conditionally sell regenerative medicine products while proceeding with its Phase 3 clinical trial.

Longeveron's Aging Frailty Research Program

Longeveron sponsors the most extensive and advanced Aging Frailty clinical research program in the world, with more than 200 patients treated with LMSCs worldwide.In the U.S., two clinical trials are currently ongoing:

About LMSCs

Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) is a regenerative medicine product sourced from the bone marrow of young healthy adult donors.LMSCs are culture expanded under the FDA's current good manufacturing practices (cGMP) to high standards, and maintained as individual "off-the-shelf" doses.

About Longeveron LLC

Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014. Longeveron's mission is to provide biological solutions for aging-related diseases and life-threatening conditions, and is dedicated to developing safe and effective cell-based therapeutics for unmet medical needs such as Aging Frailty, the Metabolic Syndrome, Alzheimer's Disease, Acute Respiratory Distress Syndrome (ARDS) from COVID-19 infection, and congenital heart defects in children (hypoplastic left heart syndrome).

SOURCE: Longeveron

Follow this link:
Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells | DNA RNA and Cells | News...